Arming an oncolytic virus with the right therapeutic payload can reshape the tumor microenvironment, amplify local immune activation, and support rational combination therapy design. Creative Biolabs provides transgene payload screening services to help researchers compare cytokines, chemokines, checkpoint-modulating molecules, bispecific engagers, prodrug-converting enzymes, tumor antigens, imaging genes, and other payload concepts within a practical oncolytic virus engineering workflow.
Armed oncolytic viruses depend on more than a promising therapeutic molecule. A payload must fit the viral backbone, remain expressible after genome insertion, preserve viral rescue and replication behavior, and produce a mechanism-relevant effect in the intended tumor or immune model.
Creative Biolabs builds payload screening plans that compare expression profile, secretion or localization, effect on viral fitness, tumor-directed function, immune activation pattern, construct stability, and downstream development fit. This creates a practical basis for prioritizing payloads before broader in vitro validation, combination therapy testing, or in vivo study planning.
Creative Biolabs supports payload screening projects from early payload concept review to comparative construct evaluation. The service can be used as a stand-alone payload selection program or integrated into broader oncolytic virus design, construction, potency assay development, and combination therapy studies.
Evaluate therapeutic rationale, tumor indication fit, mechanism of action, combination partner, translational risk, and available sequence information.
Prioritized payload candidate list with rationale and recommended screening depth.
Compare cytokines, chemokines, co-stimulatory ligands, checkpoint blockers, BiTE-like molecules, enzymes, tumor antigens, hNIS, and tracking genes.
Payload category map aligned with target biology and intended development path.
Review promoter choice, signal peptide, linker design, secretion versus anchoring, cleavage sequence, codon usage, orientation, and genome capacity constraints.
Construct design plan, sequence-ready cassette design, and risk notes for cloning or viral rescue.
Support small-panel construct preparation, viral rescue or production feasibility, and preliminary titer impact assessment where applicable.
Payload-armed construct set prepared for expression and function testing.
Measure payload mRNA or protein expression, secretion profile, cell-associated expression, dose response, and time-course behavior.
Expression dataset with construct-to-construct comparison and recommended candidates.
Run tumor killing, replication impact, immune activation, cytokine release, checkpoint modulation, prodrug conversion, or antigen presentation readouts according to payload class.
Functional ranking report and recommended next-step validation assays.
Assess payload compatibility with immune checkpoint blockade, adoptive cell therapy, bispecific engagers, chemotherapy, radiotherapy, or cancer vaccine strategies.
Combination-oriented payload recommendation and study design suggestions.
Antibody-expressing Oncolytic Virus Production 
Cytokine/Chemokine-expressing OV Production 
Immune Checkpoint Inhibitor-expressing OV Production 
OV Combination Therapy Development
The technical package is customized according to the payload class, viral platform, target cell model, and decision point. Instead of applying a single assay panel to every payload, Creative Biolabs builds a testing matrix that separates expression feasibility, viral performance, tumor-directed activity, and immune mechanism readouts.
Sequence analysis, domain architecture review, signal peptide evaluation, linker and cleavage site design, codon optimization review, and genome capacity assessment.
qPCR or RT-qPCR, ELISA, western blot, flow cytometry, reporter readout, immunofluorescence, secretion analysis, and time-course profiling.
Viral rescue feasibility, infectious titer, genome copy analysis, replication kinetics, plaque phenotype, and selected passage stability checks.
2D tumor cell panels, time-course cytotoxicity, replication-dependent killing, and spheroid or organoid-compatible assays when needed.
Immune cell co-culture, T cell or NK cell activation, cytokine/chemokine panels, antigen presentation-related markers, and checkpoint pathway readouts.
Matrix dosing, sequential or concurrent treatment design, synergy analysis, checkpoint inhibitor or cell therapy co-culture models, and biomarker readouts.
Normal cell comparators, excessive cytokine release flags, off-target activation indicators, and payload-dependent cytotoxicity profiling.
Payload candidates are not ranked by a single expression endpoint. Creative Biolabs documents the criteria used to advance one payload over another, so the final recommendation remains transparent for internal R&D review, partner discussion, or follow-up study planning.
Match between payload biology, tumor microenvironment, suppressive pathway, antigen context, and intended combination partner.
Expression level, secretion or localization, timing relative to infection and lysis, and assay-detectable dose response.
Impact on viral rescue, infectious titer, genome capacity, replication kinetics, plaque phenotype, and selected stability observations.
Tumor cell killing, immune cell activation, cytokine induction, checkpoint modulation, prodrug conversion, or antigen-related readouts.
Normal cell comparator results, nonspecific cytokine release patterns, off-target activation indicators, and payload-dependent cytotoxicity flags.
Readiness for optimized construction, in vitro validation, potency assay development, 3D model testing, or in vivo preclinical studies.
The workflow begins with a design discussion and ends with a ranked payload recommendation. Depending on the starting point, the project may start from a payload concept list, a sequence-ready construct, an existing oncolytic virus backbone, or a preliminary armed OV candidate that requires comparative optimization.
Define target indication, viral platform, payload concept, intended mechanism, model availability, and decision criteria.
Review payload sequences, expression format, localization strategy, promoter/cassette architecture, and viral capacity constraints.
Prepare payload-armed constructs or receive client-provided constructs, viral stocks, plasmids, sequences, or infected cell samples.
Measure payload expression and assess whether the transgene alters rescue, replication, titer, or genetic stability.
Run tumor cell, immune co-culture, cytokine, checkpoint, engager, enzyme, or combination assays according to payload class.
Integrate expression, activity, viral fitness, selectivity, and development feasibility into a final recommendation.
The final deliverable is designed to support a practical development decision rather than simply list assay results. Each report connects payload design choices with biological activity, viral performance, assay limitations, and recommended next steps.
Payload candidate shortlist, scientific rationale, expression cassette design notes, sequence-level recommendations, and construct architecture summary.
Confirms assay relevance, comparator logic, control design, and payload burden considerations before extensive screening.
Expression verification data with method, time point, dose or MOI context, sample type, secretion or localization information, and candidate-to-candidate comparison.
Documents experimental context so expression strength is not interpreted without timing, dose, and viral performance information.
Titer impact, replication kinetics, rescue feasibility, plaque phenotype, genome copy analysis, or selected stability readouts when included in scope.
Interprets payload activity together with viral fitness so a strong transgene is not advanced if it compromises the backbone.
Tumor cell killing, immune cell activation, cytokine profile, checkpoint pathway modulation, prodrug conversion, antigen-related readouts, or combination response.
Uses endpoints selected for payload mechanism rather than a generic OV validation panel.
Payload ranking matrix with decision criteria, risk flags, recommended candidates, and suggested follow-up work for in vitro validation, potency assay development, or in vivo studies.
Makes the reasoning behind inclusion, exclusion, or further optimization clear to project stakeholders.
This service is suitable when the central question is which therapeutic payload should be encoded by the oncolytic virus, not simply whether a virus candidate can kill tumor cells.
Compare payloads that may recruit T cells, NK cells, dendritic cells, or myeloid modulators into the tumor microenvironment.
Evaluate whether local checkpoint-modulating payloads or immune-stimulatory payloads can support anti-PD-1/PD-L1, anti-CTLA-4, or related checkpoint strategies.
Screen payloads that may enhance CAR-T, TCR-T, NK cell, or bispecific immune engager activity in tumor models.
Identify whether a transgene reduces viral replication, expression stability, or overall antitumor performance.
Test whether enzyme expression is sufficient and functionally linked to prodrug-dependent tumor killing.
Generate a payload ranking package that can guide construct finalization before potency assay development or animal studies.
Payload screening sits at the intersection of vector design and therapeutic mechanism. Creative Biolabs combines oncolytic virus engineering experience with payload design, molecular assay development, tumor cell testing, and immune functional readouts.
Assay panels are matched to the payload class and therapeutic hypothesis, improving the usefulness of the final comparison.
Projects can begin with payload concepts, sequences, plasmids, viral stocks, existing armed OV candidates, or a complete design brief.
Payload screening can connect to virus construction, expression cassette optimization, in vitro validation, potency assay development, and preclinical planning.
Results are organized into a clear ranking matrix rather than a disconnected set of assay readouts.
Screening can be designed around checkpoint inhibitors, cell therapies, bispecific engagers, prodrug systems, chemotherapy, radiotherapy, or vaccine concepts.
Questions about applicable payload types, starting materials, comparison criteria, combination therapy readouts, safety-oriented checks, and what happens after payload selection.
Creative Biolabs can support screening of cytokines, chemokines, immune co-stimulatory ligands, checkpoint-modulating molecules, antibody fragments, bispecific immune engagers, prodrug-converting enzymes, tumor antigens, reporter genes, imaging-related genes such as hNIS, and customized payload concepts. The final list is selected according to the virus backbone, tumor indication, target mechanism, expression format, and intended downstream application.
A finalized backbone is helpful, but it is not always required. Some projects begin with an established OV candidate, while others start with payload concepts and a preferred virus platform. If the backbone is not fixed, the project can first clarify payload feasibility, cassette design, genome capacity, and compatibility considerations before construct generation or side-by-side payload testing.
Payloads are compared through a predefined ranking framework. Typical criteria include expression level, secretion or localization, effect on viral rescue and replication, tumor cell killing, immune activation, cytokine profile, pathway modulation, stability, and development risk. The final recommendation balances biological activity with viral performance and practical feasibility so that the selected payload is suitable for the next development step.
Yes. For combination-focused programs, Creative Biolabs can design assays around checkpoint inhibitors, adoptive cell therapies, bispecific engagers, prodrugs, chemotherapy, radiotherapy, cancer vaccines, or other treatment partners. The purpose is to identify payloads that support the intended combination mechanism rather than select a payload only by isolated expression strength.
Useful starting information includes the target cancer type, preferred viral platform, payload candidates or sequences, intended route of administration, comparator constructs, target cell models, immune cell model preferences, previous infectivity or expression data, and any downstream milestone such as potency assay development, broader in vitro validation, or animal study planning.
Early screening can include normal cell comparators, nonspecific cytokine release monitoring, excessive immune activation flags, viral fitness assessment, and construct stability checks. These assays do not replace formal toxicology studies, but they help identify payload-related risks before the candidate enters more advanced validation or preclinical development.
After payload selection, the recommended candidate can move into optimized construct generation, broader in vitro validation, potency assay development, 3D tumor model testing, combination therapy evaluation, biodistribution planning, or in vivo preclinical studies depending on the client's development stage and the evidence package generated during screening.
To discuss a transgene payload screening project, please share your target indication, virus platform or candidate backbone, payload ideas or sequences, desired mechanism of action, available samples, preferred assay models, and intended next development milestone. Creative Biolabs can help design a screening plan that compares payload candidates with clear decision criteria and practical next-step recommendations.